CML patients often suffer a characteristic reciprocal translocation t(9:22) (q34:q11) (Philadelphia chromosome) between chromosomes 9 and 22, forming a bcr-abl fusion gene, which aberrant expresses BCR-ABL protein with continuous tyrosine kinase activity (2). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.